Mendus AB

Equities

IMMU

SE0005003654

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 03:55:57 28/05/2024 pm IST			5-day change	1st Jan Change
0.469 ^SEK	-1.26%		-1.26%	-10.33%

17/05	Transcript : Mendus AB, Q1 2024 Earnings Call, May 17, 2024
17/05	Mendus AB Announces Board Changes	CI

Immunicum AB Appoints Erik Manting as Chief Executive Officer

March 16, 2021 at 01:00 pm IST

Immunicum AB announced the establishment of an updated executive management team following the initial integration period of the business combination with DCprime that was completed in December 2020. In the new composition, the executive management team consists of Erik Manting as Chief Executive Officer (CEO).

Latest news about Mendus AB

Transcript : Mendus AB, Q1 2024 Earnings Call, May 17, 2024	17/05
Mendus AB Announces Board Changes	17/05	CI
Mendus AB Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05	CI
Mendus AB Announces Board Changes	16/04	CI
Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	27/03	CI
Transcript : Mendus AB - Special Call	12/03
Transcript : Mendus AB, 2023 Earnings Call, Feb 14, 2024	14/02
Mendus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02	CI
Certain Ordinary Shares of Mendus AB are subject to a Lock-Up Agreement Ending on 27-JAN-2024.	27/01	CI
Mendus AB Announces Clinical Pipeline Update	22/12	CI
Transcript : Mendus AB - Special Call	14/12
Mendus AB Appoints Ted Fjällman as Board Member	13/12	CI
Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023	12/12	CI
Mendus AB and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML	06/12	CI
Mendus Announces appointment of Nomination Committee for the 2024 Annual General Meeting	17/11	CI
Transcript : Mendus AB, Nine Months 2023 Earnings Call, Nov 09, 2023	09/11
Mendus AB Presents Updated Alison Clinical Trial Data for Vididencel in Ovarian Cancer At SITC 2023	06/11	CI
Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal	03/11	CI
Mendus AB Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data	02/11	CI
Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23	21/23/21	CI
Mendus Obtains US FDA's Fast Track Tag for Blood Cancer Therapy	08/23/08	MT
Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia	08/23/08	CI
Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
Mendus AB Announces the Publication of Novel Preclinical Data on its Intratumoral Priming Strategy in the Peer-Reviewed Medical Journal 'Frontiers in Immunology	16/23/16	CI
Mendus AB announced that it has received funding from Flerie Invest AB	31/23/31	CI

Chart Mendus AB

Duration

Period

More charts

Company Profile

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâs own immune system against cancer. The Companyâs programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

Sector

Biotechnology & Medical Research

Calendar

23/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mendus AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MENDUS AB	-10.33%	4.51Cr
MODERNA, INC.	+67.53%	6.39TCr
IQVIA HOLDINGS INC.	-0.77%	4.18TCr
LONZA GROUP AG	+42.95%	4.05TCr
CELLTRION, INC.	-10.02%	2.72TCr
ICON PUBLIC LIMITED COMPANY	+13.30%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	1.87TCr
BIO-TECHNE CORPORATION	+4.70%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+24.10%	1.21TCr
MEDPACE HOLDINGS, INC.	+27.41%	1.21TCr

Other Biotechnology & Medical Research